Janux reports $344M year-end cash; Q4 net loss $11.8M; positive Phase 1 JANX007/JANX008 data

Janux Therapeutics, Inc.

Year-end cash & investments $344M; net loss $58.3M for FY 2023 vs $63.1M in 2022.
Raised ~$320.2M net in March 2024 underwritten offering to fund clinical pipeline.
Phase 1 JANX007 in mCRPC: 83% PSA50 at first step dose ≥0.2mg; no CRS > Grade 2.
Phase 1 JANX008: NSCLC subject achieved RECIST PR with 100% target lesion reduction, no CRS.
Co-founder Dr. Tommy DiRaimondo promoted to CSO; JANX007 update expected 2H 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Janux Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $11.8 million for the quarter and $58.3 million for the year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Net income: Net loss was $11.8 million for the quarter and $58.3 million for the year ended December 31, 2023
Result: reported results

Exact text from the filing

Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-028647

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.